P
Peter C. Taylor
Researcher at University of Oxford
Publications - 397
Citations - 19020
Peter C. Taylor is an academic researcher from University of Oxford. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 63, co-authored 359 publications receiving 16347 citations. Previous affiliations of Peter C. Taylor include HealthPartners & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis.
Sabrina R. Kapoor,Andrew Filer,Martin Fitzpatrick,Benjamin A Fisher,Peter C. Taylor,Christopher D. Buckley,Iain B. McInnes,Karim Raza,Stephen P. Young +8 more
TL;DR: The clear relationship between urine metabolic profiles of RA patients at baseline and their response to anti-TNF therapy may allow development of novel approaches to the optimization of therapy.
Journal ArticleDOI
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial
Peter C. Taylor,Emilia Quattrocchi,Stephen Mallett,Regina Kurrasch,Jørgen Petersen,David J. Chang +5 more
TL;DR: Ofatumumab significantly improved all clinical outcomes in biological-naive, active rheumatoid arthritis patients with no detectable immunogenicity at week 24, and no unexpected safety findings were identified.
Journal ArticleDOI
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
TL;DR: Tofacitinib and baricitinib are the first orally available, small-molecule inhibitors of Janus kinase (JAK) enzymes to be approved for the treatment of RA and demonstrated rapid improvements in disease activity, function and patient-reported outcomes as well as disease modification.
Journal ArticleDOI
Antibody therapy for rheumatoid arthritis.
TL;DR: High-quality monoclonal antibodies with specificity for relevant disease molecules can now be produced in abundance and there is preliminary evidence for the clinical efficacy of both keliximab and rituximab, a chimeric mAb against the B cell antigen CD20 and CTLA4-Ig.
Journal ArticleDOI
Isolated left anterior descending coronary atherosclerosis: long-term comparison of internal mammary artery and venous autografts.
TL;DR: Recommendations for revascularization can be made selectively to patients with critical isolated left anterior descending stenoses who have limiting symptoms and large areas of viable myocardium at risk.